Perspective Therapeutics (NYSEAMERICAN:CATX) Trading Down 2.3% – Here’s Why

Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) shares were down 2.3% during trading on Monday . The company traded as low as $2.88 and last traded at $2.92. 915,349 shares were traded during trading, a decline of 60% from the average session volume of 2,297,648 shares. The stock had previously closed at $2.99.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on CATX. Wedbush restated an “outperform” rating and issued a $11.00 price target on shares of Perspective Therapeutics in a research report on Tuesday, May 5th. HC Wainwright increased their price objective on shares of Perspective Therapeutics from $12.00 to $13.00 and gave the company a “buy” rating in a research note on Monday, March 23rd. Eight equities research analysts have rated the stock with a Buy rating, According to MarketBeat, the company has an average rating of “Buy” and an average target price of $12.62.

Perspective Therapeutics Stock Down 2.3%

The stock’s fifty day simple moving average is $3.38 and its 200-day simple moving average is $3.90.

Perspective Therapeutics (NYSEAMERICAN:CATX) last posted its quarterly earnings data on Monday, May 11th. The company reported ($0.25) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.04. The business had revenue of $0.08 million during the quarter, compared to analyst estimates of $0.16 million. Perspective Therapeutics had a negative net margin of 17,982.69% and a negative return on equity of 42.33%. As a group, equities research analysts predict that Perspective Therapeutics, Inc. will post -1.1 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Taylor & Morgan Wealth Management LLC grew its position in shares of Perspective Therapeutics by 127.6% in the second quarter. Taylor & Morgan Wealth Management LLC now owns 66,000 shares of the company’s stock valued at $225,000 after purchasing an additional 37,000 shares during the period. Seven Fleet Capital Management LP purchased a new stake in Perspective Therapeutics in the 1st quarter valued at about $1,581,000. Avidity Partners Management LP grew its holdings in Perspective Therapeutics by 88.4% in the 1st quarter. Avidity Partners Management LP now owns 6,049,999 shares of the company’s stock valued at $25,228,000 after buying an additional 2,839,266 shares during the period. Ally Bridge Group NY LLC acquired a new position in shares of Perspective Therapeutics during the 1st quarter valued at about $3,864,000. Finally, Yu Fan purchased a new position in shares of Perspective Therapeutics during the 1st quarter worth about $4,401,000. Hedge funds and other institutional investors own 54.66% of the company’s stock.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.